Remote-Controlled Drug Activation Technology
Global Cancer Technology is developing a remote-controlled drug delivery platform for cancer treatments.
The key to this platform is its ability to keep a drug “inactive” until it reaches the site of a tumor. Once there, the drug is activated through a micro-dose of radiation, and can attack the tumor while keeping healthy tissue and cells unharmed.
Global Cancer Technology is led by CEO John Clark, a 25-year veteran of the medical industry. Supporting him are advisors with extensive experience in neurosurgery, cancer-related nanotechnology, and medical product commercialization.
Through a partnership with the Moores Cancer Center at UC San Diego — a top 20 hospital in the world for clinical medicine — this company has secured the exclusive license to this platform’s patented technology. Now it’s focusing on a three-stage timeline for receiving FDA approval, with hopes to commercialize its drug-delivery platform by 2024.
Global Cancer Technology’s platform is what’s referred to as a Novel Drug-Delivery System, or “NDDS.” This refers to new approaches, technologies, and systems for transporting medicine into the body.
Unlike conventional systems, NDDS combine advanced techniques with superior dosing regimens. According to Kenneth Research, a market research company, the global market for NDDS is projected to reach $320 billion by 2021.
Global Cancer Technology’s system is designed to target one of the world’s leading causes of death: cancer.
In 2019, 1.7 million Americans were diagnosed with cancer. More than 600,000 of them will die from it. According to the American Cancer Society, men and women have around a 40% chance of developing cancer in their lifetime.
Current treatment options aren’t effective, and can cause harmful side effects.
Chemotherapy, for example, attempts to eliminate cancer cells throughout a patient’s entire body. But chemo drugs can’t tell the difference between cancerous cells and healthy cells. As a result, it kills them both.
This creates debilitating side effects.
Global Cancer Technology’s drug delivery platform reduces these side effects by ensuring that cancer treatments target only the tumor. Here’s how:
The company has created a nanoparticle that attaches to a cancer-fighting drug. More specifically, cancer drug molecules are linked to Scintillating NanoCrystals, which act as the delivery vehicle and can travel throughout the body easily. This linking process is part of the patented technology Global Cancer Technology has licensed.
Because they’re linked, the cancer drug molecules are “inactive.” When the nanoparticle reaches the tumor, the Scintillating NanoCrystals are exposed to a low dose of radiation. They then “light up,” breaking the links that bind them to the cancer drug.
As a result, the previously inactive drug molecules are activated at the site of the tumor. And because the level of radiation is so low, the damage sustained to the body is significantly less compared to traditional high-dose regimens.
Global Cancer Technology has gathered pre-clinical data on its platform, and engaged in advanced conversations with companies that have proven track records in drug-delivery development. These include NantHealth (Nasdaq: NH), a company developing and marketing healthcare solutions.
NantHealth’s investors include Celgene, a biotech company with $15 billion in annual revenues, and Allscripts Healthcare Solutions (Nasdaq: MDRX).
Moving forward, Global Cancer Technology aims to complete feasibility and pre-clinical tests, followed by a six-month clinical study of its platform. This will include a Phase I human trial and tests for safety and side effects.
Once on the market, Global Cancer Technology’s platform could be leveraged by leading pharmaceutical companies, such as Novartis (NYSE: NVS), Johnson & Johnson (NYSE: JNJ), Sanofi (Nasdaq: SNY), or Eli Lilly (NYSE: LLY).
John Clark has more than 25 years of experience in the medical industry.
He was Founder and CEO of American Radiosurgery, a San Diego-based company providing surgeons with neurosurgical equipment. This was the first company in the U.S. to create a device for the use of rotating gamma technology, a surgical technique that enables doctors to more precisely treat brain tumors.
Prior to that, he was a financial partner at Endolase, a medical company focused on creating surgical lasers used in cataract surgery procedures.
John studied at the University of Scranton.
Dr. Kesari is among the top 1% of neuro-oncologists in the U.S., according to Castle Connolly Medical, a healthcare research company.
He is Chairman of the Department of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute, and is Director of NeuroOncology at Providence Saint John’s Health Center.
Dr. Kesari is on the advisory board of the American Brain Tumor Association, San Diego Brain Tumor Foundation, and the Nicolas Conor Institute.
He earned a Ph.D. in Molecular Biology and an M.D. from the University of Pennsylvania School of Medicine.
Sadik specializes in cancer nanotechnology, in-vivo imaging, and optical systems.
He is a professor of Nanoengineering and Electrical and Computer Engineering at UC, San Diego, and was Director of major research centers including the NCI-funded NanoTumor Center at UCSD.
He holds degrees in Applied Physics and Electrical Engineering.
Wolf is Head of the Chemical Biology program at the Moores Cancer Center at UC San Diego. He’s held senior level positions at The Scripps Research Institute and Columbia University.
He earned an Organic Chemistry degree from San Diego State University.
Milan is a faculty member at UC San Diego’s Moores Cancer Center, where he specializes in medical devices and imaging.
He is a member of the American Chemical Society and earned a degree in Radiation Biology from the University of Alberta.
Dr. Wolf is a radiosurgery neurosurgeon.
He’s a member of the American Medical Association and the American Association of Neurological Surgeons.
He was an associate professor at the University of Maryland and graduated summa cum laude from Yale Medical School.